[Decaris in the treatment of multiple sclerosis].
Decaris was given for 6 months to 57 patients with clinically reliably diagnosed multiple sclerosis. For evaluating the physical fitness of the patients the 10-point scoring system of Kurtzke was used. The drug was given intermittently to 2 groups of patients in a 14-day cycle of 3 tablets daily for 3 days: and in a 7-day cycle of 3 tablets for 3 days. Each tablet contained 50 mg of the drug. The effects of the drug were evaluated on the course of the disease, dynamics of neurological status changes, and side effects. The progression of the disease process was slowed down, the function of the pyramidal system and labyrinthine-cerebellar systems became normal or improved. Sphincter control was better. The best results were obtained in patients with remitting form of the disease treated in the 14-day cycle.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D006801:Humans; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011897:Random Allocation
D007978:Levamisole
Ocena preparatu Decaris w leczeniu stwardnienia rozsianego.